PGPeter John Godolphin

Peter John Godolphin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter John Godolphin has a total of 626 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Critical Appraisal Tool for Individual Participant Data Meta-analysis (CAT-IPDMA) showed variable domain-level agreement and favourable perceived usability: A developmental evaluation

    by Edith Ginika Otalike, Mike Clarke, Peter J. Godolphin, Sarah Nevitt, Fabiano Cavalcante, Andrea Tricco, Areti Angeliki Veroniki, David Moher, Larysa Rydzewska, Berend Van der Wilk, et al.

    Objective: To evaluate inter-rater agreement and usability of the Critical Appraisal Tool for Individual Participant Data Meta-analysis (CAT-IPDMA).Study Design and Setting: In this developmental evaluation, 18 raters in six sets, each comprising two trainees and one expert, independently applied CAT-IPDMA to 30 published IPD meta-analyses. Domain-level concern ratings were analyzed using ordinal-weighted Gwet’s AC2 overall and by domain, with study-level clustered bootstrap 95% confidence intervals. Usability was summarised using completion time, perceived difficulty, confidence, and UMUX-Lite scores.Results: The overall ordinal-weighted Gwet’s inter-rater agreement coefficient (AC2) is 0.40, with a 95% bootstrap CI of 0.299 to 0.503, and the agreement without chance correction was 72.8%. Exact three-rater agreement occurred in 43.9% of study-domain observations. Agreement varied across the domains, with AC2 values ranging from -0.133 to 0.853. Set-specific AC2 estimates ranged between 0.215 and 0.555. The median completion time was 40.0 minutes for trainees and 27.5 minutes for experts. Perceived difficulty was moderate, and confidence levels were generally high. The average usability (UMUX-Lite) scores were 70.8 (SD 19.9) for trainees and 73.6 (SD 16.2) for experts.Conclusion: CAT-IPDMA takes reasonable but manageable time to complete. The inter-rater agreement varied substantially across domains. The study identified areas where clearer applicability rules and domain-rating algorithms are needed before evaluation of the final version of CAT-IPDMA.

  • Open Access

    A Critical Appraisal Tool for Individual Participant Data Meta-Analyses (CAT-IPDMA): Content Validity Assessment

    by Edith Ginika Otalike, Mike Clarke, Peter J. Godolphin, Sarah Nevitt, Fabiano Cavalcante, Andrea Tricco, Areti Angeliki Veroniki, David Moher, Larysa Rydzewska, Berend Van der Wilk, et al.

    Objective: To evaluate the content validity of the critical appraisal tool for individual participant data meta-analyses (CAT IPD-MA) and iteratively refine the content and structure for practical use.,Method: This multi-phase, expert-based content validity study was embedded within the broader CAT-IPDMA development program. We purposively invited 20 experts: e-Delphi panellists who completed both survey rounds and the consensus meeting. Participants completed an online survey rating the relevance and comprehensibility of the signalling questions, grading criteria, and response options on 4-point scales. Primary quantitative outcomes were item-level content validity indices (I-CVIs), calculated as the proportion of experts assigning ratings of 3 or 4, and the average scale-level content validity index (S-CVI/Ave), calculated as the mean I-CVI across items. An I-CVI of at least 0.79 was prespecified as evidence of acceptable item-level content validity, and an S-CVI/Ave of at least 0.90 as evidence of excellent scale-level content validity. Free-text comments informed item revision.,Results: Of 20 invited experts, 13 completed the survey. The S-CVI/Ave was 0.87 for relevance and 0.91 for comprehensibility. All but one of the signalling questions met the prespecified relevance I-CVI criterion. Feedback led to rewording 12 items, splitting complex ones, and adding ”not applicable” to response options. This approach reduced the item pool to a 26-item tool across 14 domains, including 12 critical items for identifying major limitations, with standardized response options, thereby reducing respondent burden while maintaining comprehensive domain coverage. CAT-IPDMA uses domain-level judgments without a global score.,Conclusions: CAT-IPDMA demonstrates acceptable to excellent content validity as a consensus-based tool for IPD-MA quality appraisal. Relevance was supported quantitatively, comprehensibility identified targeted problems, and comprehensiveness was supported primarily by the earlier consensus phase.

  • Open Access

    Exploring Heterogeneity in Meta‐Analysis Using Trial‐Level Characteristics: A Tutorial

    by Peter J. Godolphin, Conor D. Tweed, David J. Fisher

    This tutorial describes how to explore across‐trial heterogeneity in meta‐analysis using trial‐level characteristics. It describes how to carry out a subgroup analysis for a trial‐level characteristic with more than two categories and provides approaches for analysing continuous trial‐level characteristics. The tutorial introduces meta‐regression, outlines its intended applications, and explains how to interpret meta‐regression results. Common pitfalls when undertaking trial‐level subgroup analysis and meta‐regression are also discussed. A complementary micro‐learning module is provided to support additional learning of these concepts.


  • Open Access

    Introduction to Trial‐Level Subgroup Analysis: A Tutorial

    by Peter J. Godolphin, Conor D. Tweed, David J. Fisher

    This tutorial introduces the concept of trial‐level subgroup analysis in meta‐analysis. We describe the rationale for conducting subgroup analyses, distinguish trial‐level from participant‐level characteristics, outline how to properly interpret effects within subgroups, and illustrate how to perform a trial‐level subgroup analysis, including formal statistical testing for differences between subgroups. A complementary micro‐learning module is provided to support additional learning of these concepts.


  • Intermediate- versus prophylactic-dose heparin for hospitalised patients with COVID-19: an updated meta-analysis of randomised trials

    by Peter J. Godolphin, David J. Fisher, Charlotte A. Bradbury, Srinivas Murthy, Claire L. Vale

  • Open Access

    State of play in individual participant data meta-analyses of randomised trials: Systematic review and consensus-based recommendations

    by Anna Lene Seidler, Jannik Aagerup, Lily S Nicholson, Kylie E Hunter, Ram Bajpai, Daniel G Hamilton, Thomas Love, Nadine Marlin, David Nguyen, Richard D Riley, et al.

    Background: Individual participant data (IPD) meta-analyses obtain, harmonise and synthesise the raw individual-level data from multiple studies, and are increasingly important in an era of data sharing and personalised medicine to inform clinical practice and policy. Objectives: (1) Describe the landscape of IPD meta-analysis of randomised trials over time; (2) establish current practice in design, conduct, analysis and reporting for pairwise IPD meta-analysis; and (3) derive recommendations to improve the conduct of and methods for future IPD meta-analyses. Design: Part 1: systematic review of all published IPD meta-analyses of randomised trials; Part 2: in-depth review of current methodological practice for pairwise IPD meta-analysis; and Part 3: adapted nominal group technique to derive consensus recommendations for IPD meta-analysis authors, educators and methodologists. Data sources: MEDLINE, Embase, and the Cochrane Database of Systematic Reviews (via the Ovid interface). Eligibility criteria: Part 1: all IPD meta-analyses of randomised trials published before February 2024, evaluating intervention effects and based on a systematic search. Part 2: all pairwise IPD meta-analyses from part 1 published between February 2022 and February 2024. Part 3: Selected panel of experienced IPD meta-analysis authors and/or methodologists. Results: Part 1: We identified 605 eligible IPD meta-analyses published between 1991 and 2024. The number of IPD meta-analyses published per year increased over time until 2019 but has since plateaued to about 60 per year. The most common clinical areas studied were cardiovascular disease (n=113, 19%) and cancer (n=110, 18%). The proportion of IPD meta-analyses published with Cochrane decreased over time from 16% (n=31/196) before 2015 to 3% (n=5/196) between 2021-2024. Part 2: 100 recent pairwise IPD meta-analyses were included in the in-depth review. Most cited PRISMA-IPD (68, 68%) and conducted risk of bias assessments (n=82, 82%), with just under half carrying out subgroup analyses not at risk of aggregation bias (n=36/85, 41%). However, only 33% (n=33) and 29% (n=29) respectively provided a protocol or statistical analysis plan, and only 7% (n=6/82) reported using IPD to inform risk of bias assessments. Part 3: 24 experts participated in a consensus workshop. Key recommendations for improved IPD meta-analyses focused on transparency (prospective registration; published protocols and statistical analysis plans) and maximising value (searching trial registries; obtaining IPD for unpublished evidence; using IPD to address missing data and risk of bias). Methodologists and educators should strengthen dissemination of methods and support capacity building across clinical fields and geographical areas. Conclusions: The application and methodological quality of IPD meta-analyses of randomised trials has increased in the last decade, but shortcomings remain. Implementing our consensus-based recommendations will ensure future IPD meta-analyses generate better evidence for clinical decision making. Study registration: Open Science Framework (1) Summary boxes: What is already known on this topic: IPD meta-analyses of randomised trials are regularly used to inform clinical policy and practice. They can provide better quality data and enable more thorough and robust analyses than standard aggregate data meta-analyses, but are resource-intensive and can be challenging to conduct, leading to variable methodological quality Previous studies that evaluated the conduct of IPD meta-analyses pre-date several major developments, such as the introduction of the PRISMA-IPD reporting guideline. What this study adds: This is the most comprehensive assessment of IPD meta-analyses of randomised trials to date (605 studies), showing an increase in publications over time followed by a recent plateau. The conduct of IPD meta-analysis has improved in recent years including increased use of prospective registration, assessment of risk of bias, appropriate analyses of patient subgroup effects and citing the PRISMA-IPD statement. Many shortcomings remain including (i) insufficient pre-specification of methods such as outcomes and analyses, (ii) sub-standard transparency (including publication of protocols, statistical analysis plans and reporting of analyses), and (iii) failure to gain maximum value of IPD (i.e. include unpublished trials, use the IPD to inform risk of bias and trustworthiness assessments, and address missing data appropriately); expert consensus recommendations are provided for how to address these gaps.

  • Open Access

    Examining covariate-specific treatment effects in individual participant data meta-analysis: Framing aggregation bias in terms of trial-level confounding and funnel plots

    by Lianne K. Siegel, Joseph S. Koopmeiners, Jamie Hartmann-Boyce, Peter J. Godolphin, Abdel G. Babiker, Giota Touloumi, Kirk U. Knowlton, Richard D. Riley

    To understand a treatment’s potential impact at the individual level, it is crucial to explore whether the effect differs across patient subgroups and covariate values. Meta-analysis provides an important tool for detecting treatment–covariate interactions, as it can improve power compared to a single study. However, aggregation bias can occur when estimating individual-level treatment–covariate interactions in meta-analysis, due to trial-level confounding. This refers to when the association between the covariate and treatment effect across trials (at the aggregate level) differs from that observed within trials (at the individual level). It is, thus, recommended that heterogeneity in the treatment effect at the individual level should be disentangled from that at the trial level, ideally using an individual participant data (IPD) meta-analysis. Here, we explain this issue and provide new intuition about how trial-level confounding is impacted by differences in within-trial distributions of covariates and how this corresponds to asymmetry in subgroup-specific funnel plots in the case of categorical covariates. We then propose a sensitivity analysis to assess the robustness of interaction estimates to potential trial-level confounding. We illustrate these concepts using simulated and real data from an IPD meta-analysis of trials conducted on the TICO/ACTIV-3 platform, which assessed passive immunotherapy treatments for inpatients with COVID-19.


  • Open Access

    Mechanical circulatory support for infarct-related cardiogenic shock: a systematic review, pairwise and network meta-analysis

    by Zaran Butt, Saad Sharif, Mohammed Ahmad, Michael J Daly, James O’nEill, Aleksandra Gentry-Maharaj, Peter J Godolphin

    Aims: Mortality from cardiogenic shock complicating acute myocardial infarction (AMI-CS) remains high, despite the increasing mechanical circulatory support (MCS) use in clinical practice. Methods and results: We undertook a systematic review and meta-analysis of trials assessing MCS in adults with AMI-CS. We searched Medline, EMBASE, CENTRAL, Web of Science, and Scopus from inception to May 2024. We evaluated the effect of each intervention on early mortality using a random-effects network meta-analysis of odds ratios (ORs). Safety outcomes included stroke, bleeding, and sepsis. Fourteen trials randomizing 1858 patients were included: intra-aortic balloon pump (IABP) vs. medical therapy (four trials, n = 748 patients), veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) vs. No VA-ECMO (four trials, n = 568 patients), percutaneous ventricular assist device (pVAD) vs. No pVAD (six trials, n = 542 patients). No MCS device showed a significant effect on early mortality vs. initial medical therapy {IABP (OR 0.87, 95% CI 0.66–1.15), VA-ECMO (OR 0.91, 95% CI 0.65–1.27), pVAD (OR 0.80, 95% CI 0.56–1.14), and P (inconsistency) = 0.76}. VA-ECMO and pVAD were associated with increased major bleeding [OR 2.81 (95% CI 1.68–4.71) and OR 5.13 (95% CI 1.87–14.04), respectively]. Higher rates of stroke and sepsis were noted with pVAD. No significant safety concerns were identified with IABP. Conclusion: The mortality benefit of MCS devices in AMI-CS remains uncertain. Using such devices may be associated with increased risks, including major bleeding, stroke, and sepsis. Current evidence does not support the routine use of MCS devices in the management of AMI-CS.


  • Reply to J.A. Garcia et al

    by Susan Halabi, Siyuan Guo, Akash Roy, Larysa E. Rydzewska, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael A. Carducci, et al.


  • Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

    by Susan Halabi, Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael A. Carducci, et al.

    PURPOSE: Despite major increases in the longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC), most men still die of prostate cancer. Phase III trials assessing new therapies in mHSPC with overall survival (OS) as the primary end point will take approximately a decade to complete. We investigated whether radiographic progression-free survival (rPFS) and clinical PFS (cPFS) are valid surrogates for OS in men with mHSPC and could potentially be used to expedite future phase III clinical trials. METHODS: We obtained individual patient data (IPD) from 9 eligible randomized trials comparing treatment regimens (different androgen deprivation therapy [ADT] strategies or ADT plus docetaxel in the control or research arms) in mHSPC. rPFS was defined as the time from random assignment to radiographic progression or death from any cause whichever occurred first; cPFS was defined as the time from random assignment to the date of radiographic progression, symptoms, initiation of new treatment, or death, whichever occurred first. We implemented a two-stage meta-analytic validation model where conditions of patient-level and trial-level surrogacy had to be met. We then computed the surrogate threshold effect (STE). RESULTS: IPD from 6,390 patients randomly assigned from 1994 to 2012 from 13 units were pooled for a stratified analysis. The median OS, rPFS, and cPFS were 4.3 (95% CI, 4.2 to 4.5), 2.4 (95% CI, 2.3 to 2.5), and 2.3 years (95% CI, 2.2 to 2.4), respectively. The STEs were 0.80 and 0.81 for rPFS and cPFS end points, respectively. CONCLUSION: Both rPFS and cPFS appear to be promising surrogate end points for OS. The STE of 0.80 or higher makes it viable for either rPFS or cPFS to be used as the primary end point that is surrogate for OS in phase III mHSPC trials with testosterone suppression alone as the backbone therapy and would expedite trial conduct.